Sbir phase II, topic 016: development of a bacterial synchronized lysis circuit platform to deliver therapeutics
Ended Definitive Contract Awarded Last action
- Contract number
- 75N95020C00019
- Awardee
-
Gencirq, Inc. UEI FHCTH7DWM2E3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,499,585
Award facts
- Opportunity
-
- NRRTR201018 Solicitation number
- Contract value 100% obligated
- $1,499,584.99 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Santa Barbara, CA 93109, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Vendor Address Change | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $1,499,585 |
About this award
Gencirq, Inc. was awarded a $1,499,584.99 firm fixed price definitive contract by the National Institutes of Health's National Center for Advancing Translational Sciences under the Small Business Innovation Research Program Phase II. The contract is for the development of a bacterial synchronized lysis circuit platform to deliver therapeutics, with work to be performed in Santa Barbara, California through May 2023. The award is designated as a total small business set aside. No major subcontractors were identified. This SBIR Phase II funding will support Gencirq's continued efforts to advance its lysing bacteria platform technology, which aims to use engineered bacterial cells as living drug delivery vehicles that can synchronize drug release upon reaching specific target sites in the body.
Quick answers
Who was awarded contract 75N95020C00019?
75N95020C00019 was awarded to Gencirq, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 26, 2020.
How much is contract 75N95020C00019 worth?
The government has obligated $1,499,585 on 75N95020C00019.
Which agency awarded contract 75N95020C00019?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95020C00019, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95020C00019 competed?
The extent of competition for 75N95020C00019 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award